We discuss with Michael Wechsler (National Jewish Health, Denver, CO, USA) the clinical evidence supporting the use of dupilumab in patients with asthma and specifically the major findings from the long-term safety evaluation of dupilumab in the LIBERTY ASTHMA TRAVERSE trial (NCT02134028).
1. What are the major unmet needs in the biologic treatment of moderate to severe asthma? (0:17)
2. Could you tell us a little about dupilumab, its mechanism of action and its advantages compared to other biologic therapies? (1:30)
3. What clinical evidence supports the efficacy and safety of dupilumab? (3:20)
4. Could you give us a brief overview of the LIBERTY ASTHMA TRAVERSE study and its major findings? (5:05)
5. Which patients are most likely to benefit from dupilumab therapy? (6:50)
Disclosures: Michael Wechsler has acted as a consultant for Sanofi Aventis, Regeneron, Amgen, AstraZeneca, Teva, GSK, Novartis, Genentech, Equillium, Cohero and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Barbara Yawn, CHEST 2022: The role of respiratory specialists in herpes zoster vaccination
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]
Barbara Yawn, CHEST 2022: Herpes zoster vaccination in people with asthma or chronic obstructive pulmonary disease
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University […]
Cristiano Caruso, ERS 2022: 2 Year Findings from the REALITI-A Study of Mepolizumab in Severe Asthma
REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A. The abstract ‘International, prospective study of mepolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!